The T1796A mutation of the BRAF gene is absent in Spitz nevi

被引:47
作者
Palmedo, G
Hantschke, M
Rütten, A
Mentzel, T
Hügel, H
Flaig, MJ
Yazdi, AS
Sander, CA
Kutzner, H
机构
[1] Dermatopathol Gemeinschaftspraxis, D-88048 Friedrichshafen, Germany
[2] Univ Munich, Klin Dermatol & Allergol, Munich, Germany
关键词
D O I
10.1111/j.0303-6987.2003.00179.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
Background: BRAF, a serine/threonine kinase, is a component of the retrovirus-associated sequence (RAS)-RAF-extracellular-regulated protein kinase (ERK)-MAP kinase signal transduction pathway mediating signals from RAS to ERK. The T1796A single point mutation in exon 15 of the BRAF gene has recently been reported in a high percentage of malignant melanomas and benign melanocytic lesions such as congenital nevi, compound nevi, intradermal nevi and dysplastic nevi. The T1796A mutation has been shown to promote cell proliferation. Methods: We screened 21 Spitz nevi and six spitzoid malignant melanomas for the presence of the T1796A BRAF mutation. Results: The T1796A BRAF mutation could not be detected in any of the 21 Spitz nevi but was present in two of the six spitzoid malignant melanomas. Conclusions: Our results, in conjunction with data from a previous investigation, suggest that the melanocytic proliferation of Spitz nevi might be induced by components of the RAS-RAF-ERK-MAP kinase pathway different from BRAF, possibly combined with other genetic aberrations. The lack of the T1796A BRAF mutation might be of practical importance in distinguishing Spitz nevi from other melanocytic lesions simulating Spitz nevi as a part of a future complex diagnostic assay.
引用
收藏
页码:266 / 270
页数:5
相关论文
共 9 条
[1]
Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features [J].
Bastian, BC ;
LeBoit, PE ;
Pinkel, D .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (03) :967-972
[2]
Campisi J, 2000, IN VIVO, V14, P183
[3]
Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[4]
The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[5]
Herlyn M, 1996, AM J PATHOL, V149, P739
[6]
High frequency of BRAF mutations in nevi [J].
Pollock, PM ;
Harper, UL ;
Hansen, KS ;
Yudt, LM ;
Stark, M ;
Robbins, CM ;
Moses, TY ;
Hostetter, G ;
Wagner, U ;
Kakareka, J ;
Salem, G ;
Pohida, T ;
Heenan, P ;
Duray, P ;
Kallioniemi, O ;
Hayward, NK ;
Trent, JM ;
Meltzer, PS .
NATURE GENETICS, 2003, 33 (01) :19-20
[7]
p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: Possible implications for melanoma progression [J].
Sviderskaya, EV ;
Gray-Schopfer, VC ;
Hill, SP ;
Smit, NP ;
Evans-Whipp, TJ ;
Bond, J ;
Hill, L ;
Bataille, V ;
Peters, G ;
Kipling, D ;
Wynford-Thomas, D ;
Bennett, DC .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (10) :723-732
[8]
WEINBERG RA, 1989, CANCER RES, V49, P3713
[9]
Mutations of the BRAF gene in benign and malignant melanocytic lesions [J].
Yazdi, AS ;
Palmedo, G ;
Flaig, MJ ;
Puchta, U ;
Reckwerth, A ;
Rütten, A ;
Mentzel, T ;
Hügel, H ;
Hantschke, M ;
Schmid-Wendtner, MH ;
Kutzner, H ;
Sander, CA .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (05) :1160-1162